Advertisement

Intraarterial chemotherapy for osteosarcoma: Does the result really justify the effort?

  • Stefan S. Bielack
  • Patricia Bieling
  • Rudolf Erttmann
  • Kurt Winkler
Part of the Cancer Treatment and Research book series (CTAR, volume 62)

Abstract

The use of multiagent chemotherapy has led to improved survival for osteosarcoma patients. Infusion of cisplatin by the intraarterial route in order to devitalize the primary tumor more effectively has been advocated in this context. While systemic drug levels do not seem to be compromised by this regional approach, the envisioned increase in platinum content of osteosarcoma tissue has not been substantiated.

As far as clinical results are concerned, neither a comparison of various protocols including cisplatin by either intraarterial or intravenous application, nor the only controlled study dealing with the subject (COSS 86), were able to demonstrate a correlation between the route of cisplatin administration and tumor response to chemotherapy.

Therefore, the use of the intraarterial route for cisplatin treatment of osteosarcoma cannot be considered standard therapy but is still an investigational approach without proven benefits. In addition, the risk of side effects and the increased cost of this procedure should be considered before deciding to use intraarterial treatment for osteosarcoma.

Keywords

Clin Oncol Osteosarcoma Patient Osteosarcoma Tissue Intraarterial Chemotherapy Platinum Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bacci G, Avella M, Brach del Prevert A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results. Chemiotherapia 7:138–142, 1988.Google Scholar
  2. 2.
    Benjamin RS, Raymond AK, Carrasco CH, et al. Primary chemotherapy of osteosarcoma of the extremities with systemic adriamycin and intra-arterial cisplatinum. Proc Am Soc Clin Oncol 8, abstr. 1251, 1988.Google Scholar
  3. 3.
    Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial cis-diamminedichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 63:63–67, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Sierrasesumaga L, Bilbao J, Martin Algarra S, et al. Neoadjuvant chemotherapy with intraarterial (IA) cisplatinum (CDDP) and intravenous adriamycin (ADR) prior to limb sparing tumor resection plus chemotherapy in the treatment of osteosarcoma (OS). ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 235.Google Scholar
  5. 5.
    Weiss A, Lachmann R, Berman J. (Intra-arterial preoperative chemotherapy for osteosarcoma. Proc Am Soc Clin Oncol 8:321, abstr. 1250), 1989.Google Scholar
  6. 6.
    Malawer M, Reaman G, Prienbat D, et al. Impact of a short course (2 cycles) of neoadjuvant chemotherapy with cisplatinum (DDP) and adriamycin (ADR) on the choice of surgical procedure for high-grade bone sarcomas of the extremities. Proc Am Soc Clin Oncol 8:320 (abstr. 1245), 1989.Google Scholar
  7. 7.
    Stephens FO, Tattersall MH, Marsden W, et al. Regional chemotherapy with the use of cisplatin and doxorubicin as primary treatment for advanced sarcomas in shoulder, pelvis, and thigh. Cancer 60:724–735, 1987.PubMedCrossRefGoogle Scholar
  8. 8.
    Stine KC, Hockenberry MJ, Harrelson J, et al. Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. Cancer 63:848–853, 1989.PubMedCrossRefGoogle Scholar
  9. 9.
    Trapeznikov NN, Yerimina LA, Amiraslanov AT, Sinukov PA. Management of osteosarcoma patients. Semin Surg Oncol 2:1–16, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Epelman S, Petrilli AS, Franco EL. Factors influencing survival of patients with nonmetastatic osteosarcoma treated with intra-arterial cisplatinum. Proc Am Soc Clin Oncol 6: abstr. 877, 1987.Google Scholar
  11. 11.
    Estrada J, Greenberg H, Walling AK, et al. Control of pelvic osteosarcoma (OS) with intraarterial (IA) chemotherapy and radiation therapy (XRT). Proc Am Soc Clin Oncol 7: abstr. 1075, 1988.Google Scholar
  12. 12.
    Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS 86). Cancer 66:1703–1710, 1990.PubMedCrossRefGoogle Scholar
  13. 13.
    Kahn CE Jr., Messersmith RN, Samuels BL. Brachial plexopathy as a complication of intraarterial cisplatin chemotherapy. Cardiovasc Intervent Radiol 12:47–49, 1989.PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobs SC, Menashe DS, Mewissen MW, Lipchik ED. Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 64:388–391, 1989.PubMedCrossRefGoogle Scholar
  15. 15.
    Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diam-minedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209:73–80, 1989.PubMedCrossRefGoogle Scholar
  16. 16.
    Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504, 1984.PubMedGoogle Scholar
  17. 17.
    Brock N, Pohl J. The basis of modern ifosfamide therapy. Introduction. Contrib Oncol 2:1–11, 1987.Google Scholar
  18. 18.
    Eilber F, Guiliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26, 1987.PubMedGoogle Scholar
  19. 19.
    Jaffe N. Subcutaneous reaction due to intra-arterial infusion of anthracycline. Cancer Treat Rep 68:818, 1984.PubMedGoogle Scholar
  20. 20.
    Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–623, 1984.PubMedGoogle Scholar
  21. 21.
    Hecquet B, Vennin P, Fournier C, Poissonier B. Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 47:6134–6137, 1987.PubMedGoogle Scholar
  22. 22.
    Ratto GB, Mereu C, Vannuzi M, Fulco RA. Pharmacokinetics of cisplatin pulmonary artery infusion. Fourth International Congress on Advances in Regional Cancer Therapy, June 5–7, 1989, Berchtesgaden, FRG, Cyanamid-Lederle, Arzneimittel GmbH and Co., F10, 1989.Google Scholar
  23. 23.
    Wile AG, Kar R, Cohen RA, et al. The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59:695–700, 1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Mangues Baffaluy R. Pharmacokinetic advantage of the cisplatin intra-arterial administration over intravenous route: experimental and clinical study. Diss Abstr Int (C)50:282, 1989.Google Scholar
  25. 25.
    Shani J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49:1877–1881, 1989.PubMedGoogle Scholar
  26. 26.
    Bielack S, Erttmann R, Looft G, et al. Platinum disposition after intraarterial and intravenous infusion of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 24:376–380, 1989.PubMedCrossRefGoogle Scholar
  27. 27.
    Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human tumor autopsy samples. Am J Clin Oncol 11:152–158, 1988.PubMedCrossRefGoogle Scholar
  28. 28.
    Jakowatz J, Snyder L, Ginn G, et al. Effect of route and schedule of cisplatin administration. Proc Am Soc Clin Oncol 8: abstr. 254, 1989.Google Scholar
  29. 29.
    Kishimoto S, Fukushima S, Hayashi Y, et al. Basic studies on optimal delivery rate of cisplatin. Gan Kagaku Ryohu 16:2788–2791, 1989.Google Scholar
  30. 30.
    Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.PubMedGoogle Scholar
  31. 31.
    Picci P, Bacci G, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma—results of a prospective study. In: Recent Concepts in Sarcoma Treatment. Ryan JR, Baker LH, Eds. Kluwer Academic, Dordrecht, 1988, pp 291–295.CrossRefGoogle Scholar
  32. 32.
    Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431–1432, 1986.PubMedGoogle Scholar
  33. 33.
    Ruggieri P, Picci P, Marangolo M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremies (OS): preliminary results in 116 patients (PTS) treated preoperatively with methotrexate (MTX) (IV), cisplatinum (CDP) (IA) and adriamycin (ADM). Proc Am Soc Clin Oncol 9:310 (abstr. 1199), 1990.Google Scholar
  34. 34.
    Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.PubMedGoogle Scholar
  35. 35.
    Brunat-Mentigny M, Demaille MC, Quitana E, et al. The reproduction in France of Rosen’s protocol for osteosarcomas. Bull Cancer (Paris) 75:201–206, 1988.Google Scholar
  36. 36.
    Kalifa C, Mlika N, Dubousset J, et al. Experience with protocol T10 in the pediatric service at the Gustave-Roussy institute. Bull Cancer (Paris) 75:207–211, 1988.Google Scholar
  37. 37.
    Solheim OP. Adjuvant chemotherapy in patients with osteosarcoma. ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 236.Google Scholar
  38. 38.
    Provisor A, Nachman J, Krailo M, et al. Treatment of non-metastatic osteosarcoma (OS) of the extremities with pre-and post-operative chemotherapy. Proc Am Soc Clin Oncol 6:217, 1987.Google Scholar
  39. 39.
    Green DM, Brecher ML, Douglass HO Jr., et al. The treatment of pediatric patients with osteosarcoma of an extremity. Does pre-operative intra-arterial chemotherapy affect prognosis? Proc Am Assoc Cancer Res 28:219, 1987.Google Scholar
  40. 40.
    Eilber FR, Giuliano AE, Huth JF, et al. Intravenous (IV) versus intraarterial (IA) adriamycin, 2800r radiation and surgical excision for extremely soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol 9:309 (abstr. 1194), 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Stefan S. Bielack
    • 1
  • Patricia Bieling
  • Rudolf Erttmann
  • Kurt Winkler
    • 1
  1. 1.Department of Pediatric Hematology/OncologyUniversity Children’s HospitalHamburg 20Germany

Personalised recommendations